Baxter hires Indian contractor to expand injectables pipeline

By Flora Southey

- Last updated on GMT


Related tags Pharmaceutical drug Pharmacology

Baxter International has announced an agreement with India-based Dorizoe Lifesciences to develop over 20 generic injectables, a sector it says is growing annually.

Contractor Dorizoe will help facilitate accelerated development of over 20 of Baxter’s generic molecule products, including anti-infectives, oncolytics and cardiovascular medicines.

The US-headquartered firm estimates the global sterile generic injectables segment, which it says is worth over $40bn (€35.7bn), grows by approximately 10 percent annually.

Baxter will maintain manufacturing and commercialisation rights.

The firm did not disclose financial terms of the agreement.

An injectables trend

The partnership follows Baxter’s agreement with ScinoPharm announced​ earlier this year, to develop, manufacture and commercialise up to 20 injectable cancer drugs at facilities in Germany and Taiwan.

Last year Baxter agreed​ to purchase India-based Claris Lifesciences for $625m (€598). The acquisition​, which includes three facilities in Ahmedabad, India, and a pipeline of generic injectable drug candidates, is expected to close later this year. 

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more